Associations of Neuralgic Amyotrophy with COVID-19 Vaccination: Disproportionality Analysis Using the World Health Organization Pharmacovigilance Database

Overview

Journal Muscle Nerve

Date 2022 Oct 10

PMID 36214181

Authors

Jee-Eun Kim

Jin Park

Young Gi Min

Yoon-Ho Hong

Tae-Jin Song

Affiliations

Soon will be listed here.

Abstract

Introduction/aims: There are limited studies on the association of COVID-19 vaccination with neuralgic amyotrophy (NA). Therefore, we evaluated the association between COVID-19 vaccination and the occurrence of NA.

Methods: We explored unexpected safety signals for NA related to COVID-19 vaccination through disproportionality analysis using VigiBase, the World Health Organization's pharmacovigilance database.

Results: On October 15, 2021, 335 cases of NA were identified in the database. The median time to onset of NA after vaccination was around 2 weeks. A significant signal of disproportionality of NA was observed for the ChAdOx1 nCoV-19 vaccine (AstraZeneca) (information component [IC] = 0.33, reporting odds ratio [ROR] = 1.30) and two mRNA-based COVID-19 vaccines (BNT162b2 [Pfizer and BioNTech] and mRNA-1273 [Moderna]) (IC = 1.74, ROR = 3.82) compared with the entire database. However, when compared with influenza vaccines, we did not detect any signal of disproportionality of NA for both the ChAdOx1 nCoV-19 vaccine (IC = -2.71, ROR = 0.05) and mRNA-based COVID-19 vaccines (IC = -1.38, ROR = 0.13).

Discussion: A weak association was observed between NA and COVID-19 vaccines. However, the risk did not surpass that of influenza vaccines.

Citing Articles

Parsonage-Turner Syndrome following COVID-19 Vaccination: A Systematic Review.

Rosca E, Al-Qiami A, Cornea A, Simu M Vaccines (Basel). 2024; 12(3).

PMID: 38543940 PMC: 10975425. DOI: 10.3390/vaccines12030306.

Multifocal recurrent neuralgic amyotrophy in an immunocompromised patient.

Briani C, Salvalaggio A, Anglani M, Imbergamo S, Pravato S, Marasca M J Neurol. 2024; 271(3):1080-1083.

PMID: 38184820 DOI: 10.1007/s00415-023-12157-4.

Association of Parsonage-Turner syndrome with COVID-19 infection and vaccination: a systematic review.

Ameer M, Haiy A, Bajwa M, Abeer H, Mustafa B, Ameer F J Int Med Res. 2023; 51(7):3000605231187939.

PMID: 37523491 PMC: 10392513. DOI: 10.1177/03000605231187939.

Associations of neuralgic amyotrophy with COVID-19 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database.

Kim J, Park J, Min Y, Hong Y, Song T Muscle Nerve. 2022; 66(6):766-770.

PMID: 36214181 PMC: 9874732. DOI: 10.1002/mus.27734.

References

Slade B, Leidel L, Vellozzi C, Woo E, Hua W, Sutherland A . Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009; 302(7):750-7. DOI: 10.1001/jama.2009.1201. View

Rothman K, Lanes S, Sacks S . The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004; 13(8):519-23. DOI: 10.1002/pds.1001. View

Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen A . Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer. JAMA Oncol. 2020; 6(6):865-871. PMC: 7163782. DOI: 10.1001/jamaoncol.2020.0726. View

Garg R, Paliwal V . Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci. 2021; 43(1):3-40. PMC: 8557950. DOI: 10.1007/s10072-021-05662-9. View

Bate A, Lindquist M, Edwards I, Olsson S, Orre R, Lansner A . A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998; 54(4):315-21. DOI: 10.1007/s002280050466. View

Naaber P, Tserel L, Kangro K, Sepp E, Jurjenson V, Adamson A . Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021; 10:100208. PMC: 8418937. DOI: 10.1016/j.lanepe.2021.100208. View

Kim J, Park J, Song T . A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database. Mult Scler. 2022; 28(13):2112-2123. DOI: 10.1177/13524585221109397. View

Heinz F, Stiasny K . Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 2021; 6(1):104. PMC: 8368295. DOI: 10.1038/s41541-021-00369-6. View

Min Y, Kim J, Hwang J, Shin J, Sung J, Hong Y . Parsonage-Turner syndrome following COVID-19 vaccination. J Neurol Neurosurg Psychiatry. 2022; . PMC: 9606495. DOI: 10.1136/jnnp-2021-328182. View

10.

De Bruin M, Pettersson M, Meyboom R, Hoes A, Leufkens H . Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J. 2005; 26(6):590-7. DOI: 10.1093/eurheartj/ehi092. View

11.

Park J, Park M, Kim H, Song T . Association of Cerebral Venous Thrombosis with mRNA COVID-19 Vaccines: A Disproportionality Analysis of the World Health Organization Pharmacovigilance Database. Vaccines (Basel). 2022; 10(5). PMC: 9145068. DOI: 10.3390/vaccines10050799. View

12.

van Alfen N, van Engelen B . The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain. 2005; 129(Pt 2):438-50. DOI: 10.1093/brain/awh722. View

13.

Addo I, Dadzie F, Okeke S, Boadi C, Boadu E . Duration of immunity following full vaccination against SARS-CoV-2: a systematic review. Arch Public Health. 2022; 80(1):200. PMC: 9436729. DOI: 10.1186/s13690-022-00935-x. View

14.

Noren G, Hopstadius J, Bate A . Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2011; 22(1):57-69. PMC: 6331976. DOI: 10.1177/0962280211403604. View

15.

Brown E, Wood L, Wood S . The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999; 20(2):109-17. DOI: 10.2165/00002018-199920020-00002. View

16.

Park J, Kim D, Song T . A Disproportionality Analysis for Association of Systemic Capillary Leak Syndrome with COVID-19 Vaccination Using the World Health Organization Pharmacovigilance Database. Vaccines (Basel). 2022; 10(6). PMC: 9227463. DOI: 10.3390/vaccines10060835. View

17.

Kim J, Park J, Min Y, Hong Y, Song T . Associations of neuralgic amyotrophy with COVID-19 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database. Muscle Nerve. 2022; 66(6):766-770. PMC: 9874732. DOI: 10.1002/mus.27734. View

18.

Salem J, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A . Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018; 19(12):1579-1589. PMC: 6287923. DOI: 10.1016/S1470-2045(18)30608-9. View

19.

van Eijk J, Groothuis J, van Alfen N . Neuralgic amyotrophy: An update on diagnosis, pathophysiology, and treatment. Muscle Nerve. 2015; 53(3):337-50. DOI: 10.1002/mus.25008. View